Market closed
IN8bio/$INAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IN8bio
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Ticker
$INAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
18
ISIN
US45674E1091
Website
IN8bio Metrics
BasicAdvanced
$14M
-
-$0.43
-
-
Price and volume
Market cap
$14M
52-week high
$0.29
52-week low
$0.13
Average daily volume
711K
Financial strength
Current ratio
4.303
Quick ratio
4.02
Long term debt to equity
21.871
Total debt to equity
30.785
Management effectiveness
Return on assets (TTM)
-73.25%
Return on equity (TTM)
-174.66%
Valuation
Price to book
0.98
Price to tangible book (TTM)
0.98
Price to free cash flow (TTM)
-0.548
Growth
Earnings per share change (TTM)
-51.87%
3-year earnings per share growth (CAGR)
-30.46%
IN8bio News
AllArticlesVideos
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewsWire·2 days ago
IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025
GlobeNewsWire·2 weeks ago
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for IN8bio stock?
IN8bio (INAB) has a market cap of $14M as of May 09, 2025.
What is the P/E ratio for IN8bio stock?
The price to earnings (P/E) ratio for IN8bio (INAB) stock is 0 as of May 09, 2025.
Does IN8bio stock pay dividends?
No, IN8bio (INAB) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next IN8bio dividend payment date?
IN8bio (INAB) stock does not pay dividends to its shareholders.
What is the beta indicator for IN8bio?
IN8bio (INAB) does not currently have a Beta indicator.